ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, September 9, 2013 โ Agendia, a leader in molecular cancer diagnostics, today announced that multiple established Read More
Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
โHigh Riskโ Patients with Unusual Hormone Receptors May Be Undertreated IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 27, 2013 โ Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset Read More
Molecular Subtyping Can Help Determine Prognosis and Chemotherapy Benefit in Colorectal Cancer Patients
CHICAGO โ Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO). This scientific poster Read More
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
IRVINE, CA, May 31, 2013 โ Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Read More